An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner’s lesions
- 30 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in World Journal of Urology
- Vol. 39 (6), 2065-2071
- https://doi.org/10.1007/s00345-020-03372-z
Abstract
Purpose The primary purpose of this study was to evaluate the effect of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on efficacy and safety in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The secondary purpose was to evaluate phenotyping based on Hunner’s lesions (HL). Methods In this randomized trial, adult female patients with moderate/severe IC/BPS received 12 weeks of treatment with an oral dose of ASP3652 (50, 150, or 300 mg twice daily) or placebo. A Bayesian model was employed using accumulating data to adjust the randomization probability and to analyze the primary efficacy variable (change from baseline to end of treatment in Mean Daily Pain [MDP; range 0–10]). Study outcomes and patient characteristics of patients with and without HL (HL+ and HL−) were compared. Results In total, 287 patients were randomized. The 300 mg dose group (n = 97) showed the largest effect, i.e., a mean change from baseline to end of treatment of −1.73 in MDP. However, the mean difference from placebo was 0.02. The probability that this dose was better than placebo was 13.5%. Adverse event incidence was low and similar between study groups. HL+ patients were older and had more severe symptoms than HL−. An association was suggested in HL+ patients between changes in micturition frequency and MDP (R = 0.41 [95% CI 0.18, 0.63]), which was not observed in HL− (R = 0.04 [95% CI −0.16, 0.29]). Conclusion ASP3652 was safe and well tolerated, but did not show efficacy in IC/BPS. The observed differences between HL+ and HL− suggest that IC/BPS diagnosis and treatment may be approached differently in these two phenotypes. Trial registration: EudraCT number 2011-004555-39, date of registration: 2012-05-07.Keywords
Funding Information
- Astellas Pharma, Inc.
This publication has 28 references indexed in Scilit:
- Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled TrialUrology, 2017
- The Burden of Bladder Pain in Five European Countries: A Cross-sectional StudyUrology, 2016
- Are Mast Cells Still Good Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis?Journal of Urology, 2015
- Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline AmendmentJournal of Urology, 2015
- Phenotype-directed Management of Interstitial Cystitis/Bladder Pain SyndromeUrology, 2014
- Interstitial cystitis is bladder pain syndrome with Hunner's lesionInternational Journal of Urology, 2014
- Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammationBJU International, 2010
- Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC ProposalEuropean Urology, 2008
- The Future of Cannabinoids as Analgesic Agents: A Pharmacologic, Pharmacokinetic, and Pharmacodynamic OverviewClinical Journal of Sport Medicine, 2007
- The neurobiology and evolution of cannabinoid signallingPhilosophical Transactions B, 2001